BriaCell Therapeutics Corp. (BCTX) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.32
↓-99% vs avg
5yr avg: 27.75
30Y Low0.0·High76.0
ROE
↓
-363.0%
-13% vs avg
5yr avg: -321.1%
30Y Low-419%·High-4%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BriaCell Therapeutics Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $14M | $124M | $1.0B | $1.0B | $230M | $3M | — | — | — | — |
| Enterprise Value | $-9491674 | $-374135 | $123M | $1.0B | $954M | $158M | $4M | — | — | — | — |
| P/E Ratio → | -0.05 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.32 | 0.59 | — | — | 76.03 | 6.64 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BCTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -363.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -363.0% | -363.0% | — | -664.9% | -142.7% | -113.8% | — | -4538.8% | -638.0% | -418.6% | -229.3% |
| ROA | -192.5% | -192.5% | -29.5% | -60.0% | -53.7% | -48.2% | -1022.3% | -426.3% | -275.8% | -260.3% | -211.3% |
| ROIC | -1263.2% | -1263.2% | — | — | — | — | — | -1140.6% | -689.8% | -1232.6% | -225.8% |
| ROCE | -341.6% | -341.6% | -287.7% | -71.6% | -31.0% | -26.0% | — | -4878.0% | -586.6% | -418.3% | -225.4% |
BCTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $14M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.00 | — | — | 1.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.61 | — | — | -3.97 | -2.07 | — | — | 0.42 | -1.35 | -0.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -735.71 | -735.71 | — | — | -15627.39 | -88.81 | -133.64 | -198.70 | -244.39 | — | — |
Net cash position: cash ($14M) exceeds total debt ($0)
BCTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BriaCell Therapeutics Corp.'s current ratio of 5.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 14.96x to 5.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.01 | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Quick Ratio | 5.01 | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Cash Ratio | 4.49 | 4.49 | 0.12 | 11.80 | 43.61 | 102.85 | 0.01 | 0.14 | 1.31 | 1.82 | 16.89 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
BCTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BriaCell Therapeutics Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.3% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $2M | $1M | $1M | $1M | $301305 | $47592 | $38644 | $28520 | $22647 | $19231 |
Peer Comparison
Compare BCTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCTXYou | $5M | -0.0 | — | — | — | — | -363.0% | -1263.2% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ADCT | $478M | -3.4 | — | — | 90.6% | -133.2% | — | — | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 IMCR | $2B | -57.8 | — | — | 97.9% | -11.3% | -7.1% | -17.2% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
See BCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCTX vs NKTR
Side-by-side business, growth, and profitability comparison vs Nektar Therapeutics.
Start ComparisonBCTX — Frequently Asked Questions
Quick answers to the most common questions about buying BCTX stock.
What is BriaCell Therapeutics Corp.'s P/E ratio?
BriaCell Therapeutics Corp.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is BriaCell Therapeutics Corp.'s ROE?
BriaCell Therapeutics Corp.'s return on equity (ROE) is -363.0%. The historical average is -120.0%.
Is BCTX stock overvalued?
Based on historical data, BriaCell Therapeutics Corp. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.